Cephalon Earnings Beat Consensus, But Opinion Split On Future
This article was originally published in The Pink Sheet Daily
Executive Summary
"Sentiment-driven" stock due for growth year, analyst tells "The Pink Sheet" DAILY
You may also be interested in...
Treanda Approved; Cephalon Ready With Tripled Salesforce To Launch In Chronic Lymphocytic Leukemia
Firm expects to ship product within 2-3 weeks, Cephalon tells “The Pink Sheet” DAILY.
Treanda Approved; Cephalon Ready With Tripled Salesforce To Launch In Chronic Lymphocytic Leukemia
Firm expects to ship product within 2-3 weeks, Cephalon tells “The Pink Sheet” DAILY.
Cephalon Files Treanda For NHL Indication
Chemotherapeutic has been granted a priority review for an earlier filing, for treatment of chronic lymphocytic leukemia.